-
Something wrong with this record ?
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis
T. Kalincik, V. Jokubaitis, G. Izquierdo, P. Duquette, M. Girard, P. Grammond, A. Lugaresi, C. Oreja-Guevara, R. Bergamaschi, R. Hupperts, F. Grand'Maison, E. Pucci, V. Van Pesch, C. Boz, G. Iuliano, R. Fernandez-Bolanos, S. Flechter, D....
Language English Country England, Great Britain
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 1998-01-01 to 2015-12-31
Health & Medicine (ProQuest)
from 1998-01-01 to 2015-12-31
Family Health Database (ProQuest)
from 1998-01-01 to 2015-12-31
- MeSH
- Glatiramer Acetate therapeutic use MeSH
- Immunologic Factors therapeutic use MeSH
- Interferon-beta therapeutic use MeSH
- Humans MeSH
- Registries MeSH
- Multiple Sclerosis, Relapsing-Remitting drug therapy MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
BACKGROUND: The results of head-to-head comparisons of injectable immunomodulators (interferon β, glatiramer acetate) have been inconclusive and a comprehensive analysis of their effectiveness is needed. OBJECTIVE: We aimed to compare, in a real-world setting, relapse and disability outcomes among patients with multiple sclerosis (MS) treated with injectable immunomodulators. METHODS: Pairwise analysis of the international MSBase registry data was conducted using propensity-score matching. The four injectable immunomodulators were compared in six head-to-head analyses of relapse and disability outcomes using paired mixed models or frailty proportional hazards models adjusted for magnetic resonance imaging variables. Sensitivity and power analyses were conducted. RESULTS: Of the 3326 included patients, 345-1199 patients per therapy were matched (median pairwise-censored follow-up was 3.7 years). Propensity matching eliminated >95% of the identified indication bias. Slightly lower relapse incidence was found among patients treated with glatiramer acetate or subcutaneous interferon β-1a relative to intramuscular interferon β-1a and interferon β-1b (p≤0.001). No differences in 12-month confirmed progression of disability were observed. CONCLUSION: Small but statistically significant differences in relapse outcomes exist among the injectable immunomodulators. MSBase is sufficiently powered to identify these differences and reflects practice in tertiary MS centres. While the present study controlled indication, selection and attrition bias, centre-dependent variance in data quality was likely.
AORN San Giuseppe Moscati Avellino Italy
Assaf Harofeh Medical Center Beer Yaakov Israel
Brain and Mind Research Institute Sydney Australia
Centro Internacional de Restauracion Neurologica Havana Cuba
Cliniques Universitaires Saint Luc Brussels Belgium
Craigavon Area Hospital Portadown UK
Department NEUROFARBA Section of Neurosciences University of Florence Florence Italy
Flinders University and Medical Centre Adelaide Australia
Groen Hart Ziekenhuis Gouda the Netherlands
Hôpital Notre Dame Montreal Canada
Hospital Italiano Buenos Aires Argentina
Hospital Universitario Virgen de Valme Seville Spain
Hospital Universitario Virgen Macarena Sevilla Spain
Hotel Dieu de Levis Quebec Canada
Jewish General Hospital Montreal Canada
John Hunter Hospital Newcastle Australia
Karadeniz Technical University Trabzon Turkey
MS Center Neuroscience Imaging and Clinical Sciences University 'G d'Annunzio' Chieti Italy
National Neurological Institute C Mondino Pavia Italy
Neuro Rive Sud Hôpital Charles LeMoyne Quebec Canada
Orbis Medical Center Sittard the Netherlands
Ospedale di Macerata Macerata Italy
Ospedali Riuniti di Salerno Salerno Italy
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16021025
- 003
- CZ-PrNML
- 005
- 20160729120603.0
- 007
- ta
- 008
- 160722s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1177/1352458514559865 $2 doi
- 024 7_
- $a 10.1177/1352458514559865 $2 doi
- 035 __
- $a (PubMed)25480857
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Kalincik, Tomas $u Department of Medicine, University of Melbourne, Melbourne, Australia and Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia tomas.kalincik@unimelb.edu.au.
- 245 10
- $a Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis / $c T. Kalincik, V. Jokubaitis, G. Izquierdo, P. Duquette, M. Girard, P. Grammond, A. Lugaresi, C. Oreja-Guevara, R. Bergamaschi, R. Hupperts, F. Grand'Maison, E. Pucci, V. Van Pesch, C. Boz, G. Iuliano, R. Fernandez-Bolanos, S. Flechter, D. Spitaleri, E. Cristiano, F. Verheul, J. Lechner-Scott, MP. Amato, JA. Cabrera-Gomez, ML. Saladino, M. Slee, F. Moore, O. Gray, M. Paine, M. Barnett, E. Havrdova, D. Horakova, T. Spelman, M. Trojano, H. Butzkueven, . ,
- 520 9_
- $a BACKGROUND: The results of head-to-head comparisons of injectable immunomodulators (interferon β, glatiramer acetate) have been inconclusive and a comprehensive analysis of their effectiveness is needed. OBJECTIVE: We aimed to compare, in a real-world setting, relapse and disability outcomes among patients with multiple sclerosis (MS) treated with injectable immunomodulators. METHODS: Pairwise analysis of the international MSBase registry data was conducted using propensity-score matching. The four injectable immunomodulators were compared in six head-to-head analyses of relapse and disability outcomes using paired mixed models or frailty proportional hazards models adjusted for magnetic resonance imaging variables. Sensitivity and power analyses were conducted. RESULTS: Of the 3326 included patients, 345-1199 patients per therapy were matched (median pairwise-censored follow-up was 3.7 years). Propensity matching eliminated >95% of the identified indication bias. Slightly lower relapse incidence was found among patients treated with glatiramer acetate or subcutaneous interferon β-1a relative to intramuscular interferon β-1a and interferon β-1b (p≤0.001). No differences in 12-month confirmed progression of disability were observed. CONCLUSION: Small but statistically significant differences in relapse outcomes exist among the injectable immunomodulators. MSBase is sufficiently powered to identify these differences and reflects practice in tertiary MS centres. While the present study controlled indication, selection and attrition bias, centre-dependent variance in data quality was likely.
- 650 _2
- $a glatiramer acetát $x terapeutické užití $7 D000068717
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunologické faktory $x terapeutické užití $7 D007155
- 650 _2
- $a interferon beta $x terapeutické užití $7 D016899
- 650 _2
- $a relabující-remitující roztroušená skleróza $x farmakoterapie $7 D020529
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Jokubaitis, Vilija $u Department of Medicine, University of Melbourne, Melbourne, Australia and Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.
- 700 1_
- $a Izquierdo, Guillermo $u Hospital Universitario Virgen Macarena, Sevilla, Spain.
- 700 1_
- $a Duquette, Pierre $u Hôpital Notre Dame, Montreal, Canada.
- 700 1_
- $a Girard, Marc $u Hôpital Notre Dame, Montreal, Canada.
- 700 1_
- $a Grammond, Pierre $u Hotel-Dieu de Levis, Quebec, Canada.
- 700 1_
- $a Lugaresi, Alessandra $u MS Center, Neuroscience, Imaging and Clinical Sciences, University 'G. d'Annunzio', Chieti, Italy.
- 700 1_
- $a Oreja-Guevara, Celia $u University Hospital San Carlos, IdISSC, Madrid, Spain.
- 700 1_
- $a Bergamaschi, Roberto $u National Neurological Institute C. Mondino, Pavia, Italy.
- 700 1_
- $a Hupperts, Raymond $u Orbis Medical Center, Sittard, the Netherlands.
- 700 1_
- $a Grand'Maison, Francois $u Neuro Rive-Sud, Hôpital Charles LeMoyne, Quebec, Canada.
- 700 1_
- $a Pucci, Eugenio $u Ospedale di Macerata, Macerata, Italy.
- 700 1_
- $a Van Pesch, Vincent $u Cliniques Universitaires Saint-Luc, Brussels, Belgium.
- 700 1_
- $a Boz, Cavit $u Karadeniz Technical University, Trabzon, Turkey.
- 700 1_
- $a Iuliano, Gerardo $u Ospedali Riuniti di Salerno, Salerno, Italy.
- 700 1_
- $a Fernandez-Bolanos, Ricardo $u Hospital Universitario Virgen de Valme, Seville, Spain.
- 700 1_
- $a Flechter, Shlomo $u Assaf Harofeh Medical Center, Beer-Yaakov, Israel.
- 700 1_
- $a Spitaleri, Daniele $u AORN San Giuseppe Moscati, Avellino, Italy.
- 700 1_
- $a Cristiano, Edgardo $u Hospital Italiano, Buenos Aires, Argentina.
- 700 1_
- $a Verheul, Freek $u Groen Hart Ziekenhuis, Gouda, the Netherlands.
- 700 1_
- $a Lechner-Scott, Jeannette $u John Hunter Hospital, Newcastle, Australia.
- 700 1_
- $a Amato, Maria Pia $u Department NEUROFARBA, Section of Neurosciences, University of Florence, Florence, Italy. $7 gn_A_00005308
- 700 1_
- $a Cabrera-Gomez, Jose Antonio $u Centro Internacional de Restauracion Neurologica, Havana, Cuba.
- 700 1_
- $a Saladino, Maria Laura $u INEBA, Buenos Aires, Argentina.
- 700 1_
- $a Slee, Mark $u Flinders University and Medical Centre, Adelaide, Australia.
- 700 1_
- $a Moore, Fraser $u Jewish General Hospital, Montreal, Canada.
- 700 1_
- $a Gray, Orla $u Craigavon Area Hospital, Portadown, UK.
- 700 1_
- $a Paine, Mark $u St Vincent's Hospital, Melbourne, Australia.
- 700 1_
- $a Barnett, Michael $u Brain and Mind Research Institute, Sydney, Australia.
- 700 1_
- $a Havrdova, Eva $u Department of Neurology and Center of Clinical Neuroscience, 1st Faculty of Medicine, General University Hospital and Charles University in Prague, Czech Republic.
- 700 1_
- $a Horakova, Dana $u Department of Neurology and Center of Clinical Neuroscience, 1st Faculty of Medicine, General University Hospital and Charles University in Prague, Czech Republic.
- 700 1_
- $a Spelman, Timothy $u Department of Medicine, University of Melbourne, Melbourne, Australia and Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.
- 700 1_
- $a Trojano, Maria $u Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy/These authors contributed equally to the manuscript.
- 700 1_
- $a Butzkueven, Helmut $u Department of Medicine, University of Melbourne, Melbourne, Australia, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia, and Department of Neurology, Box Hill Hospital, Monash University, Box Hill, Australia.
- 700 1_
- $a ,
- 773 0_
- $w MED00006389 $t Multiple sclerosis (Houndmills, Basingstoke, England) $x 1477-0970 $g Roč. 21, č. 9 (2015), s. 1159-71
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25480857 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160722 $b ABA008
- 991 __
- $a 20160729120827 $b ABA008
- 999 __
- $a ok $b bmc $g 1155695 $s 945553
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 21 $c 9 $d 1159-71 $e 20141205 $i 1477-0970 $m Multiple sclerosis $n Mult Scler $x MED00006389
- LZP __
- $a Pubmed-20160722
